[Federal Register: August 24, 2004 (Volume 69, Number 163)]
[Notices]
[Page 52012-52017]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr24au04-56]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Reproductive Health Research
Announcement Type: New.
Funding Opportunity Number: RFA DP05-010.
Catalog of Federal Domestic Assistance Number: 93.946.
Key Dates:
Letter of Intent Deadline: September 23, 2004.
Application Deadline: November 8, 2004.
Executive Summary: The Division of Reproductive Health has four
priority areas addressed by this announcement: (1) Maternal health, (2)
infant health, (3) unintended and teen pregnancy prevention, and (4)
women's reproductive health. This announcement seeks proposals for
etiologic or interventional research that one or more of these four
priority areas, especially as they relate to the problems of
disparities in risk, prediction of risk, and prevention of preterm
birth or unintended pregnancy. This program addresses the ``Healthy
People 2010'' focus areas of Maternal, Infant, and Child Health and
Family Planning.
I. Funding Opportunity Description
Authority: This program is authorized under Sections 301 (a) and
317 (k)(2) [42 U.S.C. 241 (a) and 247b (k)(2)] of the Public Health
Service Act, as amended.
Purpose: The purpose of the program is to generate new knowledge to
further the health of United States families and to eliminate
disparities related to contraception, pregnancy, preterm delivery, and
human reproduction.
Measurable outcomes of the program will be in alignment with one or
more of the following performance goals (1) reduce maternal morbidity
and mortality; or (2) identify biological and behavioral risk factors
influencing prematurity; (3) increase the proportion of pregnancies
that are intended; (4) reduce pregnancies among adolescent females; or
(5) increase the proportion of adolescents who abstain from sexual
intercourse or use condoms if currently sexually active.
Research Objectives:
(1) To gain a better understanding of the susceptibility to preterm
delivery, in a public health framework, through research that explores:
The social, behavioral, community, genetic, historical,
and biologic determinants of preterm birth.
The effect of gene variation within and between groups on
the risk of preterm birth, and how the environment modifies that risk.
The potential to predict the risk of preterm birth using
combinations of social, behavioral, community, genetic, historical, and
biologic determinants of preterm birth.
To gain a better understanding of the clinical use of 17-
alpha hydroxyprogesterone for the prevention of preterm delivery,
evaluate barriers to its use, and develop capacity for future expanded
studies of therapeutic effectiveness in the context of routine
obstetrical care.
(2) To prevent unintended and teen pregnancy and to improve
reproductive health among U.S. teens through innovative intervention
research, non-intervention research, and research with Latino youth.
Latinos are now the number one minority adolescent population and will
continue to grow given the population demographics of such a young U.S.
Latino population. Much of the data for Latinos are not disaggregated
by ethnic subgroups or by first or subsequent generation and,
therefore, preclude a discussion of differing risk factors and sexual
health outcomes specific to each subgroup. Latinos have the highest
teen pregnancy rate and over half of teenaged Latinos are sexually
active. They are among the
[[Page 52013]]
least likely to use contraceptives at first intercourse. Latino youth
are also disproportionately at risk for contracting sexually
transmitted infections, including HIV. Such data suggest that they are
an important target group for pregnancy prevention programs. However,
very few programs have been evaluated that are directed specifically
towards Latino teens.
(3) The principal objective of this research is the development of
knowledge to support public health prevention programs and policies,
including those that promote abstinence, reduce sexual risk taking,
improve contraceptive use including STD prevention, and improve the
delivery of reproductive health services. Proposals may include
epidemiologic, behavioral, clinical, ethnographic, contextual-level,
ecologic, and other research, both qualitative and quantitative.
(Research that focuses primarily on school-based curriculum approaches
will not be supported under this announcement.)
Activities:
Recipient activities for this program are as follows:
(1) Preterm Delivery:
Using existing standardized assays, or creating new
standard assays where standards do not exist, track the natural history
of inflammatory biomarkers for preterm delivery through the course of
pregnancy in an ethnically and racially diverse cohort of pregnant
women in the United States. Biomarkers should include, but are not
limited to, mediators of inflammation (cytokines, chemokines). Stored
biologic specimens for women (blood, cervical swabs, vaginal swabs) and
infant (cord blood, buccal swabs) dyads in this cohort will facilitate
further analyses such as exploring the gene polymorphisms associated
with variation in the inflammatory response. In addition to serial
biological specimens, a broad range of social, behavioral, community,
historical, and biologic determinants of preterm birth, and obstetrical
data as well as pregnancy outcomes must be collected so that we might
better understand the factors associated with an increased
susceptibility to preterm delivery.
Perform studies to explore the association between the
presence of potential genetic markers for up-regulating or down-
regulating inflammatory mediators and preterm birth in an ethnically
and racially diverse cohort of U.S. women and their infants. The nature
and design of these studies necessitate an existing cohort about which
exists a broad range of social, behavioral, community, historical, and
biologic determinants of preterm birth, and obstetrical data, stored
biological samples for women and infant dyads, and pregnancy and
neonatal outcomes.
Describe the use of 17-alpha hydroxyprogesterone in the
setting of routine clinical practice in representative sample of health
care providers treating socially and racially diverse populations.
Evaluate provider and patient acceptance of progesterone therapy.
Examine patient compliance with weekly clinic visits and injections,
according to obstetrical history, risk factors, social, behavioral,
community, historical, and biologic determinants of preterm birth.
Evaluate barriers to patient adherence and potential novel solutions.
Develop capacity for possible future expanded assessments of
therapeutic effectiveness of progesterone preparations in the context
of routine clinical care.
(2) Unintended and Teen Pregnancy Prevention:
Intervention Research Objective: To gain a better
understanding of factors associated with successful programs to prevent
unintended and teen pregnancy through rigorous, innovative intervention
research. Potential projects could include:
[cir] Youth development or parent interventions which incorporate
reproductive health promotion;
[cir] Innovative approaches to providing clinical services which
incorporate behavior change interventions into clinical settings;
[cir] Programmatic ways to improve contraceptive practice and
contraceptive adherence;
[cir] Intervention research tailored to the cultural circumstances
of specific communities;
[cir] Culturally appropriate adaptations to teen pregnancy
prevention programs to address the needs for culturally diverse youth;
[cir] Community-level interventions, such as use of radio drama or
community outreach workers, to prevent unintended pregnancy and to
promote reproductive health;
[cir] Interventions that target health care providers and youth
service workers to better meet needs of clients in diverse populations.
Non-Intervention Research Objective: To increase knowledge
of factors associated with risk of unintended and teen pregnancy and
related health consequences through innovative research. Potential
projects could include:
[cir] Delayed initiation of first intercourse among teens or
promotion of abstinence among sexually experienced teens;
[cir] Social and cultural forces that shape pregnancy intentions
and reproductive decision-making including contraceptive use,
childbearing, and HIV/STD prevention;
[cir] Sensitivity and appropriateness of unintended pregnancy
measures in diverse and disempowered populations;
[cir] Determinants of incorrect or inconsistent use of
contraception and factors associated with highly effective use;
[cir] Issues of gender and male involvement in sexual behavior and
decision making, abstinence, contraceptive use, and pregnancy outcome;
[cir] Risks for unintended pregnancy and STDs among gay, lesbian,
bisexual, transgender, and questioning youth;
[cir] Differences between racial and ethnic subgroups in adolescent
pregnancy rates, antecedents, and associated factors;
[cir] Efforts to improve the measurement of pregnancy intentions
and factors related to teen pregnancy and unintended pregnancy;
[cir] Methodological research designed to improve research
approaches and public health surveillance for teen and unintended
pregnancy;
[cir] Migration and acculturation processes as they relate to
reproductive health outcomes and wantedness and intendedness of
pregnancy;
[cir] Social and cultural influences, including gender dynamics, on
abstinence, sexual risk behavior, and contraceptive use;
[cir] Longitudinal research projects examining sexual development,
life planning, and pregnancy-related intentions and behaviors in
diverse populations.
Latino Youth Objective: To gain a better understanding of
the risk for unintended and teen pregnancy and associated health
outcomes among Latino youth through research. Potential projects could
include:
[cir] Social and cultural determinants of pregnancy intentions,
contraceptive use, and HIV/STD prevention among diverse Latino ethnic
subgroups and in diverse settings, e.g., along the U.S.-Mexico border;
[cir] Sensitivity and appropriateness of unintended pregnancy
measures in Latino populations;
[cir] Ways that migration and acculturation interact with
reproductive health behaviors and outcomes;
[cir] The meaning and measurement of acculturation processes as
they relate to reproductive health outcomes and wantedness and
intendedness of pregnancy among Latina youth;
[[Page 52014]]
[cir] Issues of gender and male involvement in sexual behavior and
decision making, abstinence, contraceptive use, and pregnancy outcome;
[cir] Longitudinal research projects.
In a cooperative agreement, CDC staff is substantially involved in
the program activities, above and beyond routine grant monitoring.
CDC Activities for this program are as follows:
(1) Assist in development of the research protocol by providing
scientific consultation and technical assistance.
(2) Facilitate movement of the initial research protocol through
CDC IRB as well as keeping CDC IRB abreast of protocol amendments and
facilitating annual reviews.
(3) Assist in data analyses and interpretation and the presentation
and publication of findings.
(4) Conduct site visits to recipient institution to determine the
progress of the research and to monitor performance against approved
project objectives.
(5) Establish agreements for sharing data and access to biological
specimens.
(6) Facilitate distribution and dissemination of research findings,
especially to state and local health departments and other grantees.
II. Award Information
Type of Award: Cooperative Agreement. CDC involvement in this
program is listed in the Activities Section above.
Fiscal Year Funds: Fiscal Year 2005.
Approximate Total Funding: $4,500,000.
$1,500,000 for preterm delivery.
$3,000,000 for unintended and teen pregnancy prevention. (The
estimated funding amount is pending availability of FY 2005 funds, and
is subject to change.)
Approximate Number of Awards: At least six total, including a
minimum of one for each of the three activities under preterm delivery
and one for each of the three objectives under unintended and teen
pregnancy prevention activities.
Approximate Average Award: $500,000 (This amount is for the first
12-month budget period, and includes both direct and indirect costs)
for the preterm delivery and teen and unintended pregnancy intervention
projects; and $300,000 for the teen and unintended pregnancy non-
intervention and Latino projects.
Floor of Award Range: None.
Ceiling of Award Range: $600,000 for preterm delivery and teen and
unintended pregnancy intervention projects; $350,000 for non-
intervention and Latino projects.
Anticipated Award Date: January 15, 2005.
Budget Period Length: 12 months.
Project Period Length: Up to five years.
Throughout the project period, CDC's commitment to continuation of
awards will be conditioned on the availability of funds, evidence of
satisfactory progress by the recipient (as documented in required
reports), and the determination that continued funding is in the best
interest of the Federal Government.
III. Eligibility Information
III.1. Eligible Applicants
Applications may be submitted by public and private nonprofit and
for profit organizations and by governments and their agencies, such
as:
Public nonprofit organizations.
Private nonprofit organizations.
For profit organizations.
Small, minority, women-owned businesses.
Universities.
Colleges.
Research institutions.
Hospitals.
Community-based organizations.
Faith-based organizations.
Federally recognized Indian tribal governments.
Indian tribes.
Indian tribal organizations.
State and local governments or their Bona Fide Agents
(this includes the District of Columbia, the Commonwealth of Puerto
Rico, the Virgin Islands, the Commonwealth of the Northern Marianna
Islands, American Samoa, Guam, the Federated States of Micronesia, the
Republic of the Marshall Islands, and the Republic of Palau).
Political subdivisions of States, in consultation with
States.
A Bona Fide Agent is an agency/organization identified by
the state as eligible to submit an application under the state
eligibility in lieu of a state application. If you are applying as a
bona fide agent of a state or local government, you must provide a
letter from the state or local government as documentation of your
status. Place this documentation behind the first page of your
application form.
III.2. Cost Sharing or Matching
Matching funds are not required for this program.
III.3. Other
If you request a funding amount greater than the ceiling of the
award range, your application will be considered non-responsive, and
will not be entered into the review process. You will be notified that
your application did not meet the submission requirements.
If your application is incomplete or non-responsive to the
requirements listed in this section, it will not be entered into the
review process. You will be notified that your application did not meet
submission requirements.
Individuals Eligible to Become Principal Investigators: Any
individual with the skills, knowledge, and resources necessary to carry
out the proposed research is invited to work with their institution to
develop an application for support. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are
always encouraged to apply for CDC programs.
Note: Title 2 of the United States Code section 1611 states that
an organization described in section 501(c)(4) of the Internal
Revenue Code that engages in lobbying activities is not eligible to
receive Federal funds constituting an award, grant, or loan.
IV. Application and Submission Information
IV.1. Address To Request Application Package
To apply for this funding opportunity, use application form PHS 398
(OMB number 0925-0001 rev. 5/2001). Forms and instructions are
available in an interactive format on the CDC Web site, at the
following Internet address: http: //http://www.cdc.gov/od/pgo/forminfo.htm.
Forms and instructions are also available in an interactive format
on the National Institutes of Health (NIH) Web site at the following
Internet address: http://grants.nih.gov/grants/funding/phs398/phs398.html
.
If you do not have access to the Internet, or if you have
difficulty accessing the forms on-line, you may contact the CDC
Procurement and Grants Office Technical Information Management Section
(PGO-TIM) staff at: 770-488-2700. Application forms can be mailed to
you.
IV.2. Content and Form of Application Submission
Letter of Intent (LOI): Your LOI must be written in the following
format:
Maximum number of pages: Two.
Font size: 12-point unreduced.
Single spaced.
Paper size: 8.5 by 11 inches.
Page margin size: One inch.
Printed only on one side of page.
Written in plain language, avoid jargon.
Your LOI must contain the following information:
[[Page 52015]]
Descriptive title of the proposed research.
Name, address, E-mail address, and telephone number of the
Principal Investigator.
Names of other key personnel.
Participating institutions.
Number and title of this Program Announcement (PA).
Application: Follow the PHS 398 application instructions for
content and formatting of your application. For further assistance with
the PHS 398 application form, contact PGO-TIM staff at 770-488-2700, or
contact GrantsInfo, Telephone (301) 435-0714, E-mail:
GrantsInfo@nih.gov.
Your research plan should address activities to be conducted over
the entire project period.
You are required to have a Dun and Bradstreet Data Universal
Numbering System (DUNS) number to apply for a grant or cooperative
agreement from the Federal government. Your DUNS number must be entered
on line 11 of the face page of the PHS 398 application form. The DUNS
number is a nine-digit identification number, which uniquely identifies
business entities. Obtaining a DUNS number is easy and there is no
charge. To obtain a DUNS number, access http://www.dunandbradstreet.com
or call 1-866-705-5711.
For more information, see the CDC Web site at: http://www.cdc.gov/od/pgo/funding/pubcommt.htm
.
This PA uses just-in-time concepts. It also uses the modular
budgeting as well as non-modular budgeting formats. See: http://grants.nih.gov/grants/funding/modular/modular.htm
for additional
guidance on modular budgets. Specifically, if you are submitting an
application with direct costs in each year of $250,000 or less, use the
modular budget format. Otherwise, follow the instructions for non-
modular budget research grant applications.
Additional requirements that may require you to submit additional
documentation with your application are listed in section ``VI.2.
Administrative and National Policy Requirements.''
IV.3. Submission Dates and Times
LOI Deadline Date: September 23, 2004.
CDC requests that you send a LOI if you intend to apply for this
program. Although the LOI is not required, not binding, and does not
enter into the review of your subsequent application, the LOI will be
used to gauge the level of interest in this program, and to allow CDC
to plan the application review.
Application Deadline Date: November 8, 2004.
Explanation of Deadlines: Applications must be received in the CDC
Procurement and Grants Office by 4 p.m. Eastern Time on the deadline
date. If you send your application by the United States Postal Service
or commercial delivery service, you must ensure that the carrier will
be able to guarantee delivery of the application by the closing date
and time. If CDC receives your application after closing due to: (1)
Carrier error, when the carrier accepted the package with a guarantee
for delivery by the closing date and time, or (2) significant weather
delays or natural disasters, you will be given the opportunity to
submit documentation of the carriers guarantee. If the documentation
verifies a carrier problem, CDC will consider the application as having
been received by the deadline.
This announcement is the definitive guide on LOI and application
content, submission address, and deadline. It supersedes information
provided in the application instructions. If your application does not
meet the deadline above, it will not be eligible for review, and will
be discarded. You will be notified that your application did not meet
the submission requirements.
CDC will not notify you upon receipt of your application. If you
have a question about the receipt of your application, first contact
your courier. If you still have a question, contact the PGO-TIM staff
at: 770-488-2700. Before calling, please wait two to three days after
the application deadline. This will allow time for applications to be
processed and logged.
IV.4. Intergovernmental Review of Applications
Your application is subject to Intergovernmental Review of Federal
Programs, as governed by Executive Order (EO) 12372. This order sets up
a system for state and local governmental review of proposed federal
assistance applications. You should contact your state single point of
contact (SPOC) as early as possible to alert the SPOC to prospective
applications, and to receive instructions on your state's process.
Click on the following link to get the current SPOC list: http://www.whitehouse.gov/omb/grants/spoc.html
.
IV.5. Funding Restrictions
None.
If you are requesting indirect costs in your budget, you must
include a copy of your indirect cost rate agreement. If your indirect
cost rate is a provisional rate, the agreement should be less than 12
months of age.
IV.6. Other Submission Requirements
LOI Submission Address: Submit your LOI by express mail, delivery
service, fax, or E-mail to: Brenda Colley-Gilbert, Scientific Review
Administrator, CDC, NCCDPHP, 4770 Buford Highway, NE.,Mail Stop
K22,Atlanta, GA 30341-3717,Telephone: 770-488-6295,Fax: 770-488-7291,E-
mail: BJC4@cdc.gov.
Application Submission Address: Submit the original and three hard
copies of your application by mail or express delivery service
to:Technical Information Management-RFA DP05-010, CDC
Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-
3717.
At the time of submission, two additional copies of the application
must be sent to: Brenda Colley-Gilbert, Scientific Review
Administrator, CDC, NCCDPHP, 4770 Buford Highway, NE.,Mail Stop
K22,Atlanta, GA 30341-3717,Telephone: 770-488-6295,Fax: 770-488-7291,E-
mail: BJC4@cdc.gov.
Applications may not be submitted electronically at this time.
V. Application Review Information
V.1. Criteria
You are required to provide measures of effectiveness that will
demonstrate the accomplishment of the various identified objectives of
the cooperative agreement. Measures of effectiveness must relate to the
performance goals stated in the ``Purpose'' section of this
announcement. Measures must be objective and quantitative, and must
measure the intended outcome. These measures of effectiveness must be
submitted with the application and will be an element of evaluation.
The goals of CDC-supported research are to advance the
understanding of biological systems, improve the control and prevention
of disease and injury, and enhance health. In the written comments,
reviewers will be asked to evaluate the application in order to judge
the likelihood that the proposed research will have a substantial
impact on the pursuit of these goals.
The scientific review group will address and consider each of the
following criteria in assigning the application's overall score,
weighting them as appropriate for each application. The application
does not need to be strong in all categories to be judged likely to
have major scientific impact and thus deserve a high priority score.
For example, an investigator may propose to carry out important work
that by its nature is not innovative, but is essential to move a field
forward.
[[Page 52016]]
The criteria are as follows:
Significance: Does this study address an important problem? If the
aims of the application are achieved, how will scientific knowledge be
advanced? What will be the effect of these studies on the concepts or
methods that drive this field?
Approach: Are the conceptual framework, design, methods, and
analyses adequately developed, well-integrated, and appropriate to the
aims of the project? Does the applicant acknowledge potential problem
areas and consider alternative tactics?
[cir] For preterm delivery only: It is critical to the design of
this project that the study population be of sufficient ethnic and
racial diversity to study differences in risk factors, biomarkers, and
gene-environment interactions for white and black race and Hispanic
ethnicity.
Innovation: Does the project employ novel concepts, approaches or
methods? Are the aims original and innovative? Does the project
challenge existing paradigms or develop new methodologies or
technologies?
Investigator: Is the investigator appropriately trained and well
suited to carry out this work? Is the work proposed appropriate to the
experience level of the principal investigator and other researchers?
[cir] For preterm delivery only: The principal investigator or the
co-principal investigator must have a history of conducting
competitively funded peer reviewed research directed at exploring the
etiology or determinants of preterm delivery or directed at
understanding the susceptibility of preterm delivery. The results of
this research must have been published in peer reviewed journals within
the last five years.
[cir] For preterm delivery only: In addition, the applicant's
project team must include significant expertise in research on the
relationships between infection and inflammation and preterm birth. For
genetic studies, the team must include expertise in the area of the
genetic regulation of the production of inflammatory mediators. At
least one member of the project team must have laboratory experience in
developing assays for inflammatory mediators (e.g. chemokines,
cytokines), stress hormones (e.g. corticotrophin releasing hormone),
and in the case of genetic studies, determination of polymorphism
status (e.g. single and multiplex polymerase chain reaction).
Environment: Does the scientific environment in which the work will
be done contribute to the probability of success? Do the proposed
experiments take advantage of unique features of the scientific
environment or employ useful collaborative arrangements? Is there
evidence of institutional support?
[cir] For preterm delivery only: For studies involving
prospectively-collected information, the applicant must document the
existence of the appropriate institutional research infrastructure to
carry out a large, complex project as well as the facilities to handle,
store, and analyze biological samples for activities that require
collection, storage, and analysis of such samples. There must be
demonstrated ability to recruit women early in pregnancy and retain
them throughout the course of their pregnancy.
Protection of Human Subjects from Research Risks: Does the
application adequately address the requirements of Title 45 CFR part 46
for the protection of human subjects? This will not be scored; however,
an application can be disapproved if the research risks are
sufficiently serious and protection against risks is so inadequate as
to make the entire application unacceptable.
Inclusion of Women and Minorities in Research: Does the application
adequately address the CDC Policy requirements regarding the inclusion
of women, ethnic, and racial groups in the proposed research? This
includes: (1) The proposed plan for the inclusion of both sexes and
racial and ethnic minority populations for appropriate representation;
(2) the proposed justification when representation is limited or
absent; (3) a statement as to whether the design of the study is
adequate to measure differences when warranted; and (4) a statement as
to whether the plans for recruitment and outreach for study
participants include the process of establishing partnerships with
communities and recognition of mutual benefits.
Budget: The reasonableness of the proposed budget and the requested
period of support in relation to the proposed research.
V.2. Review and Selection Process
Applications will be reviewed for completeness by the Procurement
and Grants Office (PGO) and for responsiveness by the National Center
for Chronic Disease Prevention and Heath Promotion (NCCDPHP).
Incomplete applications and applications that are non-responsive to the
eligibility criteria will not advance through the review process.
Applicants will be notified that their application did not meet
submission requirements.
Applications that are complete and responsive to the PA will be
evaluated for scientific and technical merit by an appropriate peer
review group or charter study section convened by NCCDPHP in accordance
with the review criteria listed above. As part of the initial merit
review, all applications may:
Undergo a process in which only those applications deemed
to have the highest scientific merit, generally the top half of the
applications under review, will be discussed and assigned a priority
score.
Receive a written critique.
Receive a second level review by the NCCDPHP Extramural
Research Review Group.
Award Criteria: Criteria that will be used to make award decisions
include:
Scientific merit (as determined by peer review).
Availability of funds.
Programmatic priorities.
V.3. Anticipated Award Date
CDC expects to make awards on or about January 15, 2005.
VI. Award Administration Information
VI.1. Award Notices
Successful applicants will receive a Notice of Grant Award (NGA)
from the CDC Procurement and Grants Office. The NGA shall be the only
binding, authorizing document between the recipient and CDC. The NGA
will be signed by an authorized Grants Management Officer, and mailed
to the recipient fiscal officer identified in the application.
Unsuccessful applicants will receive notification of the results of
the application review by mail.
VI.2. Administrative and National Policy Requirements
45 CFR part 74 and part 92
For more information on the Code of Federal Regulations, see the
National Archives and Records Administration at the following Internet
address: http://www.access.gpo.gov/nara/cfr/cfr-table-search.html.
The following additional requirements apply to this project:
AR-1 Human Subjects Requirements.
AR-2 Requirements for Inclusion of Women and Racial and
Ethnic Minorities in Research.
AR-4 HIV/AIDS Confidentiality Provisions.
AR-5 HIV Program Review Panel Requirements.
AR-6 Patient Care.
AR-7 Executive Order 12372.
AR-8 Public Health System Reporting Requirements.
AR-9 Paperwork Reduction Act Requirements.
[[Page 52017]]
AR-10 Smoke-Free Workplace Requirements.
AR-11 Healthy People 2010.
AR-12 Lobbying Restrictions.
AR-14 Accounting System Requirements.
AR-15 Proof of Non-Profit Status.
AR-21 Small, Minority, and Women-Owned Business.
AR-22 Research Integrity.
AR-23 States and Faith-Based Organizations.
AR-24 Health Insurance Portability and Accountability Act
Requirements.
AR-25 Release and Sharing of Data.
Additional information on these requirements can be found on the
CDC Web site at the following Internet address: http://www.cdc.gov/od/pgo/funding/ARs.htm
.
VI.3. Reporting
You must provide CDC with an original, plus two hard copies of the
following reports:
1. Interim progress report, (use form PHS 2590, OMB Number 0925-
0001, rev. 5/2001 as posted on the CDC website) no less than 90 days
before the end of the budget period. The progress report will serve as
your non-competing continuation application, and must contain the
following elements:
a. Current Budget Period Activities Objectives.
b. Current Budget Period Financial Progress.
c. New Budget Period Program Proposed Activity Objectives.
d. Budget.
e. Additional Requested Information.
f. Measures of Effectiveness.
2. Financial status report and annual progress report no more than
90 days after the end of the budget period.
3. Final financial and performance reports, no more than 90 days
after the end of the project period.
These reports must be mailed to the Grants Management Specialist
listed in the ``Agency Contacts'' section of this announcement.
VII. Agency Contacts
For general questions about this announcement, contact: Technical
Information Management Section, CDC Procurement and Grants Office, 2920
Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-2700.
For scientific/research issues, contact: Brenda Colley Gilbert,
Extramural Project Officer, NCCDPHP/Deputy Associate Director for
Extramural Research (DADER), 4770 Buford Highway, NE., Mail Stop K20,
Atlanta, GA 30341-3717, Telephone: 770-488-6295, E-mail:
BColleyGilbert@CDC.GOV.
For questions about peer review, contact: Brenda Colley Gilbert,
Scientific Review Administrator, 4770 Buford Highway, NE., Mail Stop
K20, Atlanta, GA 30341-3717, Telephone: 770-488-6295, E-mail:
BColleyGilbert@CDC.GOV.
For financial, grants management, or budget assistance, contact:
Tracey Sims, Grants Management Specialist, CDC Procurement and Grants
Office, 2920 Brandywine Road, Atlanta, GA 30341, Telephone: 770-488-
2739, E-mail: Tsims3@cdc.gov.
VIII. Other Information
This and other CDC funding opportunity announcements can be found
on the CDC Web site, Internet address: http://www.cdc.gov. Click on
``Funding'' then ``Grants and Cooperative Agreements.''
Dated: August 17, 2004.
William P. Nichols,
Acting Director, Procurement and Grants Office, Centers for Disease
Control and Prevention.
[FR Doc. 04-19310 Filed 8-23-04; 8:45 am]
BILLING CODE 4163-18-P